These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 15228615)
41. Biological agents: a novel approach to the therapy of rheumatoid arthritis. Lorenz HM Expert Opin Investig Drugs; 2000 Jul; 9(7):1479-90. PubMed ID: 11060753 [TBL] [Abstract][Full Text] [Related]
42. Etanercept in the treatment of rheumatoid arthritis. Haraoui B; Bykerk V Ther Clin Risk Manag; 2007 Mar; 3(1):99-105. PubMed ID: 18360618 [TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of the anti-TNF biologic agents. Weaver AL Mod Rheumatol; 2004; 14(2):101-12. PubMed ID: 17143658 [TBL] [Abstract][Full Text] [Related]
45. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Schaeverbeke T; Truchetet ME; Kostine M; Barnetche T; Bannwarth B; Richez C Rheumatology (Oxford); 2016 Feb; 55(2):210-20. PubMed ID: 26268816 [TBL] [Abstract][Full Text] [Related]
46. Recurrent pneumothorax after etanercept therapy in a rheumatoid arthritis patient: a case report. Kim SH; Choi SJ; Seo YH; Kim JH; Jeong IW; Sohn SB Chonnam Med J; 2014 Dec; 50(3):115-8. PubMed ID: 25568848 [TBL] [Abstract][Full Text] [Related]
47. Outcome of patients with rheumatoid arthritis treated by step-wise administration of disease-modifying antirheumatic drugs over a 10-year period. Hamada Y; Shinomiya F; Okada M; Fujimura T Mod Rheumatol; 2003 Mar; 13(1):27-34. PubMed ID: 24387113 [TBL] [Abstract][Full Text] [Related]
48. Eight-year preservation of knee function with radiographic healing phenomena after anti-tumor necrosis factor-α therapy for a severely erosive knee in a young patient with rheumatoid arthritis. Nishikawa M; Owaki H; Kaneshiro S; Fuji T Acta Reumatol Port; 2015; 40(1):72-6. PubMed ID: 25782531 [TBL] [Abstract][Full Text] [Related]
53. Immunotherapy for rheumatoid arthritis. Taylor PC; Williams RO; Maini RN Curr Opin Immunol; 2001 Oct; 13(5):611-6. PubMed ID: 11544014 [TBL] [Abstract][Full Text] [Related]
54. Bone and TNF in rheumatoid arthritis: clinical implications. Manara M; Sinigaglia L RMD Open; 2015; 1(Suppl 1):e000065. PubMed ID: 26557382 [TBL] [Abstract][Full Text] [Related]
55. Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development. Demin I; Hamrén B; Luttringer O; Pillai G; Jung T Clin Pharmacol Ther; 2012 Sep; 92(3):352-9. PubMed ID: 22760002 [TBL] [Abstract][Full Text] [Related]
56. Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Douni E; Sfikakis PP; Haralambous S; Fernandes P; Kollias G Arthritis Res Ther; 2004; 6(1):R65-R72. PubMed ID: 14979939 [TBL] [Abstract][Full Text] [Related]
57. A Review of the Use of Biological Agents in Human Immunodeficiency Virus Positive Patients With Rheumatological Diseases. Attallah MA; Jarrin Jara MD; Gautam AS; Peesapati VSR; Khan S Cureus; 2020 Oct; 12(10):e10970. PubMed ID: 33209528 [TBL] [Abstract][Full Text] [Related]
58. Case report of transverse myelitis in a patient receiving etanercept for rheumatoid arthritis. Defty H; Sames E; Doherty T; Hughes R Case Rep Rheumatol; 2013; 2013():728371. PubMed ID: 23573450 [TBL] [Abstract][Full Text] [Related]